4 Gene Therapy Stocks to Watch in 2017
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Your trusted source for investing success
Your trusted source for investing success
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Reports have indicated to the growth for the industry based on the curiosity and need for patients to find new therapies involved to their diseases.
We look at four types of gene editing currently in clinical trials, as well as the pros and cons of each.
The week’s top gainer was Ocular Therapeutix, followed by Cara Therapeutics, Immunomedics, Rockwell Medical and Array BioPharma.
By Pia Rivera
Last week’s top gainer was PTC Therapeutics followed by Cogentix Medical, Concordia International, Galectin Therapeutics and XOMA.
By Emma Harwood
Last week’s top gainer was AveXis, Inc. followed by Heska Corp., Corcept Therapeutics, Atara Biotherapeutics and Seattle Genetics Inc.
By Vivien Diniz
This month, investors can expect some new blood to enter the life science market, with five companies — Editas Medicine, BeiGene, Protestasis Therapeutics, AveXis, Cancer Prevention Pharmaceuticals— listing on the NASDAQ.
By Vivien Diniz
AveXis, Inc., announced patient enrollment has completed for the Phase 1 clinical trial of AVXS-101 for the treatment of spinal muscular atrophy (SMA) Type 1.
